CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has 11 years of Assets Average data on file, last reported at $2.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 13.22% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 13.22% YoY), and the FY2025 full-year result was $2.3 billion, up 0.8% from the prior year.
• Assets Average improved to $2.5 billion in Q1 2026, from $2.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.7 billion in Q1 2022 to a low of $2.1 billion in Q2 2025.
• A 5-year average of $2.3 billion and a median of $2.3 billion in 2025 frame the typical range for Assets Average.
• Peak annual rise in Assets Average reached 41.53% in 2022, while the deepest fall reached 17.53% in 2022.
• Tracing CRSP's Assets Average over 5 years: stood at $2.3 billion in 2022, then declined by 6.09% to $2.2 billion in 2023, then grew by 4.21% to $2.2 billion in 2024, then advanced by 0.28% to $2.3 billion in 2025, then grew by 10.65% to $2.5 billion in 2026.
• Business Quant data shows CRSP's Assets Average at $2.5 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.1 billion in Q3 2025.